RESEARCH TRIANGLE PARK, N.C., and PARIS – November 16, 2010 – Quintiles, the world’s leading bio pharmaceutical services company, and Kadrige, the market leader in e-detailing and multichannel sales solutions for the pharmaceutical and healthcare industries, today announced a global alliance that brings innovative models to physician detailing to help biotech and pharmaceutical companies increase productivity, overcome complexity and more efficiently demonstrate value for their therapies.
Through a co-promotion agreement covering Europe and the United States, Quintiles and Kadrige will enable biotech and pharma customers to reduce one of their largest fixed costs by transitioning from a traditional healthcare visit model to a “hybrid” model that blends face-to-face physician discussions with live, remote e-detailing calls via the telephone and internet. The co-promotion agreement also enables Quintiles and Kadrige to develop Web-Call centers, which allow medical sales representatives to train or call healthcare professionals on a full-time basis.
This alliance is the first of its kind in the industry. Kadrige and Quintiles’ joint offering provides the full continuum of services and solutions required to evolve smoothly from an aging promotional model to a new one, based on the smart mix of multiple channels of communication that will bring to the biotech or pharma company, cost reductions, sales impact increase and a much larger flexibility to react to market evolutions.
“With Kadrige, we can revolutionize the lifecycle implementation of a brand by customizing physician detailing in accordance with its lifecycle need,” said Michael Ackermann, Senior Vice President of Commercialization for Quintiles. “We are committed to helping our customers succeed in the New Health, and these innovative hybrid call center and multichannel models are the transformative solutions our customers require.”
“While many companies are piloting a hybrid approach, our agreement with Quintiles provides a real-world solution that saves customers time and money by delivering the right message at the right time to the right target through the right channel,” Kadrige Founder and Chairman Olivier Cadou said. “This agreement expands our presence in the U.S. and Europe through access to the largest biotech and pharma sales force in the world.”
Quintiles is the only fully integrated bio pharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps bio pharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.
Kadrige is the European leader in SaaS (Software-as-a-Service) e-detailing and e-conferencing solutions. Its deep understanding of the complex requirements of pharmaceutical industry professionals has enabled the development of a range of high performance and innovative solutions and services. Kadrige offers software solutions intended for health care sales forces, as well as an ongoing support program, enabling a smooth transition from a classical health care visit model toward a “hybrid” model which brings a much higher return on investment. With this hybrid model, medical sales representatives can smartly blend face-to-face promotions of their products to health care professionals, and remote live e-detailing visits by combining telephone and internet. Founded in 2002, Kadrige has near to 60 employees and several clients in 15 countries which are ranked in the top 20 pharmaceutical company ratings. For more information, please visit www.kadrige.com.
This press release contains “forward-looking statements,” based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Risks and uncertainties include, among other things, general industry conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products; inconsistency of treatment results among patients; the potential for product failures; potential difficulties in manufacturing; governmental laws and regulations affecting domestic and foreign operations and the ongoing success of the collaboration. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required to do so by law.